These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27815174)

  • 1. Comparative biodistribution and safety profiling of olmesartan medoxomil oil-in-water oral nanoemulsion.
    Gorain B; Choudhury H; Tekade RK; Karan S; Jaisankar P; Pal TK
    Regul Toxicol Pharmacol; 2016 Dec; 82():20-31. PubMed ID: 27815174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats.
    Gorain B; Choudhury H; Kundu A; Sarkar L; Karmakar S; Jaisankar P; Pal TK
    Colloids Surf B Biointerfaces; 2014 Mar; 115():286-94. PubMed ID: 24388859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.
    Nooli M; Chella N; Kulhari H; Shastri NR; Sistla R
    Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COMPARATIVE BIOAVAILABILITY OF A FIXED-DOSE COMBINATION TABLET OF OLMESARTAN MEDOXOMIL/HYDROCHLOROTHIAZIDE IN HEALTHY KOREAN VOLUNTEERS.
    Zheng R; Hwang HM; Kim BH
    Acta Pol Pharm; 2016; 73(2):509-16. PubMed ID: 27180444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment.
    Kamran M; Ahad A; Aqil M; Imam SS; Sultana Y; Ali A
    Int J Pharm; 2016 May; 505(1-2):147-58. PubMed ID: 27005906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability.
    Kaithwas V; Dora CP; Kushwah V; Jain S
    Colloids Surf B Biointerfaces; 2017 Jun; 154():10-20. PubMed ID: 28284054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and development of a self-microemulsifying drug delivery system of olmesartan medoxomil for enhanced bioavailability.
    Komesli Y; Burak Ozkaya A; Ugur Ergur B; Kirilmaz L; Karasulu E
    Drug Dev Ind Pharm; 2019 Aug; 45(8):1292-1305. PubMed ID: 30986085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro and In Vivo Evaluation of Olmesartan Medoxomil Microcrysta ls and Nanocrystals: Preparation, Characterization, and Pharmacokinet ic Comparison in Beagle Dogs.
    Chai R; Gao H; Ma Z; Guo M; Fu Q; Liu H; He Z
    Curr Drug Deliv; 2019; 16(6):500-510. PubMed ID: 31244438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers.
    Alsofany JM; Hamza MY; Abdelbary AA
    AAPS PharmSciTech; 2018 Jul; 19(5):2118-2132. PubMed ID: 29700766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positively charged self-nanoemulsifying oily formulations of olmesartan medoxomil: Systematic development, in vitro, ex vivo and in vivo evaluation.
    Beg S; Sharma G; Thanki K; Jain S; Katare OP; Singh B
    Int J Pharm; 2015 Sep; 493(1-2):466-82. PubMed ID: 26211900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals.
    Jain S; Patel K; Arora S; Reddy VA; Dora CP
    Drug Deliv Transl Res; 2017 Apr; 7(2):292-303. PubMed ID: 28116656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats.
    Nakamoto T; Harasawa H; Akimoto K; Hirata H; Kaneko H; Kaneko N; Sorimachi K
    Eur J Pharmacol; 2005 Dec; 528(1-3):43-51. PubMed ID: 16336959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability.
    Lee BS; Kang MJ; Choi WS; Choi YB; Kim HS; Lee SK; Lee J; Choi YW
    Arch Pharm Res; 2009 Nov; 32(11):1629-35. PubMed ID: 20091278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
    Nagaraj K; Narendar D; Kishan V
    Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid lipid nanoparticles as an efficient drug delivery system of olmesartan medoxomil for the treatment of hypertension.
    Pandya NT; Jani P; Vanza J; Tandel H
    Colloids Surf B Biointerfaces; 2018 May; 165():37-44. PubMed ID: 29453084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
    Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
    Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment.
    Albash R; El-Nabarawi MA; Refai H; Abdelbary AA
    Int J Nanomedicine; 2019; 14():6555-6574. PubMed ID: 31616143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation of lyophilized oily-core poly-Ɛ-caprolactone nanocapsules to improve oral bioavailability of Olmesartan Medoxomil.
    Khattab WM; Zein El-Dein EE; El-Gizawy SA
    Drug Dev Ind Pharm; 2020 May; 46(5):795-805. PubMed ID: 32275456
    [No Abstract]   [Full Text] [Related]  

  • 20. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.
    Brunner HR
    J Hum Hypertens; 2002 May; 16 Suppl 2():S13-6. PubMed ID: 11967728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.